Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxford BioMedica ( (GB:OXB) ) has issued an announcement.
Oxford Biomedica has secured a new four-year loan facility of up to $125 million from Oaktree Capital Management to support its global CDMO operations and growth strategy. This financial move will refinance an existing $50 million loan and provide flexibility for future business needs, reinforcing OXB’s position in the cell and gene therapy industry and demonstrating Oaktree’s confidence in the company’s strategic objectives and market leadership.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s stock score is driven by strong earnings call insights and positive corporate events, indicating potential for future growth. However, financial performance remains a concern with high leverage and ongoing profitability challenges. Technical indicators suggest bullish momentum, but caution is advised due to potential overbought conditions.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organization (CDMO) in cell and gene therapy, with a mission to enable its clients to deliver life-changing therapies to patients worldwide. With 30 years of experience, OXB specializes in viral vector development and manufacturing, collaborating with leading pharmaceutical and biotechnology companies. The company offers a range of technologies for viral vector manufacturing and has facilities in the UK, France, and the US.
Average Trading Volume: 152,381
Technical Sentiment Signal: Buy
Current Market Cap: £467M
See more insights into OXB stock on TipRanks’ Stock Analysis page.